myPBCteam

Great question! The two newer PBC medications — seladelpar (Livdelzi) and elafibranor (Iqirvo) — were both FDA-approved in 2024, so they are relatively new to the market.

The clinical trial data that led to their approval showed promising results:

- Seladelpar reduced ALP levels in many patients, with about 25% seeing Show Full Answer

Great question! The two newer PBC medications — seladelpar (Livdelzi) and elafibranor (Iqirvo) — were both FDA-approved in 2024, so they are relatively new to the market.

The clinical trial data that led to their approval showed promising results:

- Seladelpar reduced ALP levels in many patients, with about 25% seeing levels return to normal, and it significantly reduced itching with no serious treatment-related side effects reported during trials.
- Elafibranor also targets liver inflammation through similar pathways and showed positive results leading to its approval. Because these medications are relatively new, long-term real-world data is still being gathered. It's worth having a conversation with a hepatologist (liver specialist) about what the current evidence shows and whether either option might be a good fit based on individual health history and lab results.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

New Treatments for PBC: How They Work and Side Effects

Primary Biliary Cholangitis Treatments and Their Side Effects